Authors:
Jingyuan Wang, Joanne Xiu, Yasmine Baca, Richard M. Goldberg, Philip A. Philip, Andreas Seeber, Francesca Battaglin, Hiroyuki Arai, Shivani Soni, Ryuma Tokunaga, Wu Zhang, Jimmy J. Hwang, Anthony F. Shields, John L. Marshall, Igor Astaturov, A. Craig Lockhart, Zoran Gatalica, W. Michael Korn, Heinz-Josef Lenz
Conclusions:
This is the largest study to investigate the distinct genomic landscape between KMT2-MT and WT GC to date. Our data indicates that GC patients with KMT2 mutations could potentially benefit from agents targeting DNA damage repair and immunotherapy. Efficiency of these therapeutic targets in KMT2-MT GC warrant further in vitro and in vivo investigation.
Download PublicationCookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |